Join
Live feed
·
PRReleasevia Quantisnow
BridgeBio Pharma Inc. logo

Oral Infigratinib Shows Meaningful Benefits Beyond Growth Within 52 Weeks in Children with Achondroplasia in the Phase 3 PROPEL 3 Trial

ByQuantisnow·Wall Street's wire, on your screen.
BBIO· BridgeBio Pharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BBIO (BridgeBio Pharma Inc.) and more on Quantisnow.